(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -24.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Cytomx Therapeutics's revenue in 2025 is $147,557,000.On average, 4 Wall Street analysts forecast CTMX's revenue for 2025 to be $8,982,824,466, with the lowest CTMX revenue forecast at $5,998,224,199, and the highest CTMX revenue forecast at $12,536,611,062. On average, 2 Wall Street analysts forecast CTMX's revenue for 2026 to be $4,694,174,785, with the lowest CTMX revenue forecast at $1,205,288,330, and the highest CTMX revenue forecast at $8,183,061,240.
In 2027, CTMX is forecast to generate $6,107,062,945 in revenue, with the lowest revenue forecast at $4,031,145,271 and the highest revenue forecast at $8,183,061,240.